Department of Vascular Surgery, Dedinje Cardiovascular Institute, Belgrade University School of Medicine, 11040 Belgrade, Serbia.
Laboratory of Radiobiology and Molecular Genetics, Institute of Nuclear Sciences Vinca, University of Belgrade, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia.
Curr Vasc Pharmacol. 2019;17(3):291-297. doi: 10.2174/1570161116666180209111826.
Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.
慢性静脉疾病(CVeD)在普通人群中是一种高发疾病,它对生活质量有显著影响。虽然 CVeD 通常表现为明显的症状,如静脉曲张和静脉溃疡,但该疾病的其他症状则不那么具有特异性。在其他症状中,包括沉重感、肿胀、肌肉痉挛和不宁腿,疼痛是最常迫使 CVeD 患者寻求医疗帮助的症状。然而,疼痛的严重程度与临床上可检测到的 CVeD 迹象之间存在显著差异,这一点受到了一些相互矛盾的研究的质疑。需要进一步评估来澄清这个问题,并分析疼痛的发展是否预示着 CVeD 的客观进展。CVeD 的一般管理从建议生活方式改变开始,如降低体重指数和治疗合并症。然而,治疗的主要方法是压迫疗法,并额外使用药物。已经证明,静脉活性药物是缓解症状和减缓 CVeD 进展的首选药物,其中微粒化纯化黄酮类混合物是最有效的药物。介入治疗保留给疾病的晚期阶段。